血清PGC、PG亞群與胃癌前病變相關(guān)性及柴胡疏肝散加減的治療作用觀察

胡萍　張國(guó)新　宋冬梅　嚴(yán)海榮

【摘要】 目的：觀察與探究血清PGC、PG亞群與胃癌前病變相關(guān)性及柴胡疏肝散加減的治療作用。方法：選取2014年11月-2017年3月本院診治的70例胃癌前病變患者為觀察組，同時(shí)期的70例非萎縮性胃炎患者為對(duì)照組。檢測(cè)與比較兩組患者的血清PGC、PG亞群水平，并比較觀察組中不同分類者的檢測(cè)結(jié)果，采用Logistic回歸分析處理血清PGC、PG亞群與胃癌前病變的關(guān)系。比較觀察組中常規(guī)治療與常規(guī)治療聯(lián)合柴胡疏肝散加減患者的臨床療效、治療前后的血清PGC、PG亞群水平。結(jié)果：觀察組的血清PGC高于對(duì)照組（P<0.05），血清PGⅠ及PGR均低于對(duì)照組（P<0.05），而血清PGⅡ無(wú)明顯差異（P>0.05），且不同分類者的血清PGC、PGⅠ及PGR比較，差異均有統(tǒng)計(jì)學(xué)意義（P<0.05），Logistic回歸分析顯示，血清PGC、PGⅠ及PGR均與胃癌前病變有密切的關(guān)系，且常規(guī)治療聯(lián)合柴胡疏肝散加減治療患者的臨床療效好于常規(guī)治療，治療后的血清PGC、PGⅠ及PGR好于常規(guī)治療（P<0.05）。結(jié)論：血清PGC、PG亞群與胃癌前病變有密切的關(guān)系，且柴胡疏肝散加減的治療作用較好，對(duì)上述血清指標(biāo)有較好的調(diào)節(jié)作用。

【關(guān)鍵詞】 血清； PGC； PG亞群； 胃癌前病變； 柴胡疏肝散加減

Observation on the Correlation between Serum PGC，PG Subpopulations and Gastric Precancerous Lesions and Treatment Effect of Modification Chaihu Shugan Powder/HU Ping，ZHANG Guoxin，SONG Dongmei，et al.//Medical Innovation of China，2017，14（35）：013-016

【Abstract】 Objective：To observe and investigate the correlation between serum PGC，PG subpopulations and gastric precancerous lesions and treatment effect of Modification Chaihu Shugan Powder.Method：70 patients with gastric precancerous lesions in our hospital from November 2014 to March 2017 were selected as the observation group，70 patients with non-atrophic gastritis at the same time were selected as the control group.Then the serum PGC and PG subpopulations levels of two groups were detected and compared，then the detection results of the observation group with different types were compared，and the relationship between serum PGC，PG subpopulations and gastric precancerous lesions were analyzed with Logistic regression analysis.Then clinical effect，serum PGC and PG subpopulations levels before and after the treatment of the observation group with conventional treatment and conventional treatment combined with Modification Chaihu Shugan Powder were compared.Result：The serum PGC of the observation group was higher than that of the control group（P<0.05），the serum PGⅠ and PGR were lower than those of the control group（P<0.05），while the serum PGⅡ had no obvious difference（P>0.05），and the serum PGC，PGⅠ and PGR of patients with different types were compared，the differences were significant differences（P<0.05），Logistic regression analysis showed the serum PGC，PGⅠ and PGR all had close relationship to gastric precancerous lesions，the clinical effect of patients with conventional treatment combined with Modification Chaihu Shugan Powder was better than that of conventional treatment，and PGC，PGⅠ and PGR after the treatment were better than those of conventional treatment（P<0.05）.Conclusion：The serum PGC and PG subpopulations have close relationship to the gastric precancerous lesions，and the treatment effect of Modification Chaihu Shugan Powder is better，so it has a better adjustment role to those serum indexes.endprint

【Key words】 Serum； PGC； PG subpopulations； Gastric precancerous lesions； Modification Chaihu Shugan Powder

First-authors address：Jiangsu Shengze Hospital，Suzhou 215200，China

doi：10.3969/j.issn.1674-4985.2017.35.004

胃癌前病變是臨床并不少見(jiàn)的一類易于發(fā)生癌變的胃黏膜組織病變，主要表現(xiàn)為腸上皮化生及異型增生[1]，因此特殊性臨床對(duì)胃癌前病變的重視程度極高，與本病診斷、治療相關(guān)方面的研究也多見(jiàn)，其中PGC及PG亞群是胃部分泌及與之相關(guān)的胃蛋白酶及其前體，對(duì)于胃部狀態(tài)的反應(yīng)價(jià)值較高。近年來(lái)臨床中關(guān)于胃癌前病變治療的相關(guān)研究多見(jiàn)[2-3]，其中中藥治療作用的研究不斷增多，而柴胡疏肝散是常見(jiàn)有效藥物之一，但是對(duì)于本類藥物對(duì)患者上述血清PGC、PG亞群的影響研究十分不足。本文中筆者就血清PGC、PG亞群與胃癌前病變相關(guān)性及柴胡疏肝散加減的治療作用進(jìn)行觀察，現(xiàn)報(bào)道如下。

1 資料與方法

1.1 一般資料 選取2014年11月-2017年3月本院診治的70例胃癌前病變患者為觀察組，同時(shí)期的70例非萎縮性胃炎患者為對(duì)照組。……